Preparing Your Audit Response: Corrective and Preventative Action Plans (CAPAs)

Similar documents
Quality Monitoring Checklist

Pre-Questions. Mastering Clinical Research July 29, 2015

Guide to Completing a Graduate Degree

Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure

No Page 1 of 5. Issue Date 4/21/2014

Data Management & Case Report Form Development in Clinical Trials. Introduction to the Principles and Practice of Clinical Research.

Friday, May 2. Clinical Trials: Is Your Staff Competent? Session 10:15 11:45 am Ballroom C

The Regulatory Binder/Trial Master File: Essential Records for the Conduct of a Clinical Trial

Prepared by: Clinical Trials Monitoring Branch Cancer Therapy Evaluation Branch Division of Cancer Treatment and Diagnosis National Cancer Institute

Investigator responsibilities for research conducted under the authority of the UTHSCSA Institutional Review Board (IRB)

The Commonwealth of Massachusetts AUDITOR OF THE COMMONWEALTH

The Monitoring Visit. Denise Owensby, CCRP Sr. Clinical Research Coordinator Clinical & Translational Science Center University of California, Davis

Introduction to Data Auditing

Document Title: Trust Approval and Research Governance

MASTER OF PUBLIC HEALTH PROGRAM

Clinical Investigator Inspections and FDA-483 Observations

Laurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute

Sharon H. Johnson, BS, MS 123 Main Street Capital City, VA Phone:

ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014

Hollie Goddard Sr. IRB Coordinator McKesson Specialty Health

Marie-Claire Rickard, GCP & Governance Manager Rachel Fay, GCP & Governance Manager Elizabeth Clough, R&D Operations Manager

Development of Case Report Forms

The Ontario Cancer Research Ethics Board Overview

Health Canada s GCP Compliance Program Part 2. GCP Information Sessions November 2010

Fundamentals of Clinical Trial Financial Management

Review current regulatory climate Budget development Coverage analysis Charge reconciliation / 3 rd party billing Lessons learned

NEGOTIATING CLINICAL TRIAL BUDGETS. Debbie Williams R.N., C.C.R.C., C.R.A., A.B.N.

California Medical Transaction Data Quality Assurance Program

National Home Inspector Certification Council. Policy & Procedures Manual

2. For all clinical trials, the coverage analysis will also be audited to ensure compliance with the Medicare National Coverage Determination.

Determining who the investigators are and who the principal investigator is:

LLED Doctoral Program Requirements

POLICY SUBJECT: EFFECTIVE DATE: 5/31/2013. To be reviewed at least annually by the Ethics & Compliance Committee COMPLIANCE PLAN OVERVIEW

ICH CRA Certification Guide March 2009

The Importance of Following the PROTOCOL in Clinical Trials

STANDARD OPERATING PROCEDURE NO. CM

Reliance Agreement for Institutions Utilizing Stony Brook University s Institutional Review Board(s)

Bloomfield College Staff Employee Performance Review

Electronic Medical Records and Source Data for Research: What s the Difference?

Scholarly Project and Thesis Guidelines. for the. MSON Graduate Nursing Programs

Roles & Responsibilities of the Sponsor

Guidance for Industry and FDA Staff FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND Frequently Asked Questions

To Certify or Not to Certify

To Certify or Not to Certify Sandra Halvorson, BA, CCRP

Appendix 1 CPI Learning Activities (2 nd to 5 th Semesters)

This unit will provide the structure needed to achieve successful supervision and oversight of the study. We will explain the importance of an

UNITED STATES DEPARTMENT OF EDUCATION OFFICE OF INSPECTOR GENERAL. December 10, 2015

Using Social Media in Research: Regulatory and IRB Considerations

New York City Department of Buildings

GUIDELINES FOR DOCTORAL STUDENT PARTICIPATION IN GRADUATION CEREMONY AND PROGRESS TO DEGREE AWARD

CULTURAL STUDIES GRADUATE GROUP DEGREE REQUIREMENTS Revisions: June 2006, February 2009 Approved by Graduate Council: May 20, 2009

Core Training Outline

11/10/2011. History of CBUs. 10-CBA providing access to unlicensed cord blood units. The FDA s involvement. The FDA s involvement, cont.

Provider Monitoring Process

ADMINISTRATIVE MANUAL Subject: CORPORATE RESPONSIBILITY Directive #: Present Date: January 2011

POLICE OFFICER (EMPLOYEE) EVALUATION

University of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol

Revenue Cycle Assessment

GxP Process Management Software. White Paper: Ten Most Common Reasons for FDA 483 Observations and Warning Letter Citations

The University of Texas Health Science Center at Houston Institutional Healthcare Billing Compliance Plan JANUARY 14, 2013

DHHS/NIH/OD/OIR/OHSRP 1/2/2015

DAIDS Bethesda, MD USA POLICY. Requirements for Clinical Quality Management Plans

National Institute for Health Research Coordinated System for gaining NHS Permission (NIHR CSP)

Orientation Manual for Clinical Research Coordinators

GUIDE TO WORK TERM 6

Version history Version number Version date Effective date 01 dd-mon-yyyy dd-mon-yyyy 02 dd-mon-yyyy dd-mon-yyyy 03 (current) dd-mon-yyyy dd-mon-yyyy

Investigational Drugs: Investigational Drugs and Biologics

Guidance on Withdrawal of Subjects from Research: Data Retention and Other Related Issues

Role of IRB/IEC in GCP. Benjamin Kuo, MD, Dr.PH, CIP.

REPORT 2016/045 INTERNAL AUDIT DIVISION. Audit of contracts management in the African Union-United Nations Hybrid Operation in Darfur

Guide. Minister s Guide to Auditing for Building Surveyors. April 2014

Implementing Regulations under the Benelux Convention on Intellectual Property (Trademarks and Designs) *

Med Sync YOUR STEP-BY-STEP QUICK REFERENCE GUIDE

Slide 4. Slide 5. Agent Transfer Form: Top Section Containing Transfer From Investigator and Transfer Reason

Accreditation of qualifications for registration as an oral health practitioner

PREP Course #27: Medical Device Clinical Trial Management

Nonconformities (NCs) and Observations (OBs)

SAMPLE INSURANCE BROKER SERVICE AGREEMENT

Network Monitoring Handbook

Lisa A. Benson, BS CCRP, CRCP 9 Vexation Hill Drive Rocky Hill, Connecticut labenso@connecticutchildrens.

Objectives. Monitoring & Auditing of Clinical Trials. Overview. Pre-study Qualification Visit. Industry-sponsored Trials

UNIVERSITY OF CALIFORNIA, DAVIS INTERNAL AUDIT SERVICES

CALIFORNIA ALTERNATIVE ENERGY AND ADVANCED TRANSPORTATION FINANCING AUTHORITY Meeting Date: February 18, 2014

LATE SUBMISSION OF TRAVEL EXPENSE CLAIMS, UNFILED TRAVEL EXPENSE REPORTS, AND RECONCILIATION OF PREPAID EXPENSES

Los Angeles County Metropolitan Transportation Authority Office of the Inspector General Medicare Part B Reimbursements to Retirees

Clinical Trials (Post Award and CRMS) Dorothy Damron, Oncology Research Manager and CRMS Lead Scott Streibich, Clinical Research Revenue Cycle

HD 599 Thesis Research (6) or HD 598 Research Practicum (6)

Management Programmes. Dissertation Student Guidelines

Transcription:

Preparing Your Audit Response: Corrective and Preventative Action Plans (CAPAs) Barbara Barrett, Audit Program Director Alliance Chicago Office Alliance Fall 2014 Group Meeting

CAPAs and Good Clinical Practice Goals of CAPAs: l Assess to measure l Measure to correct l Correct to prevent l Prevent to achieve l [SoCRA SOURCE August 2012]

CAPAs and Good Clinical Practice Preventing errors in the future: 1) Eliminates potential patient safety issues 2) Provides cleaner research data 3) Saves time for staff and lead group 4) Ultimately reduces costs

Audit Exit Interview Reminders Take notes throughout the audit and at the Exit Interview Make sure to understand the comments from the Exit Interview - don t be afraid to ask questions

The Final Audit Report (behind the scenes) Team Leader creates a draft audit report and resolves any outstanding issues with the site A second review is conducted to check for accuracy and consistency between sites

The Final Report (behind the scenes) The final version is submitted in the CTMB via the AIS (Audit Information System) electronic database An electronic version of the final audit report is emailed to the Principal Investigator and Lead CRA - plus hard copies are sent Fed Ex.

Audit Report Distribution to Affiliates and Components It is the Main Member s or NCORP s responsibility to review the audit report with affiliate(s)/components

Understanding the Audit Report Reminder of three audit components: IRB/ Consent Content Pharmacy Patient Case Review

Understanding the Audit Report Category ratings: OK (no deficiency is warranted) Lesser Deficiency (minor deficiency) Major Deficiency (significant error or omission)

Understanding the Audit Report Overall Category Assessment: Acceptable No follow-up is needed Acceptable Needs Follow-up corrective and preventative action plan required within 15 business days Unacceptable As above and re-audit scheduled within 12 months required

If you received an Unacceptable rating Alliance Policy - An Unacceptable rating in any section of the audit is evaluated on a case-bycase basis and may warrant immediate suspension of registration privileges Should a suspension occur, it will be lifted when a response is submitted and found to be Acceptable

Sample Audit Reports

Audit Report Cover Letter Summarizes the three ratings: The IRB/Consent Content review was rated Acceptable Needs Follow-up. The deficiencies includes... Pharmacy review was rated Acceptable. The Patient Case review was rated Unacceptable. The deficiencies include. Provides a date the CAPA is due: A written corrective and preventative action plan addressing the deficiencies in these areas must be submitted by Tuesday, December 16, 2014.

Submission of CAPAs CAPAs must include: - Corrective measures taken for deficiencies (e.g., submission of outstanding data, correction and submission of data errors, or IRB submission of missed protocol updates) - Measures for prevention of deficiencies in the future, e.g. revision of your P&Ps, additional training, discussion with IRB regarding procedures and timelines, re-education of staff involved - ***Happy to review draft CAPAs***

Submission of CAPAs Author(s) of CAPA should be identified CAPA MUST be submitted on letterhead and signed by the PI, plus any other author(s) Attach any pertinent support documentation (submit amended CRFs to the data center) No need to attach copy of your audit report Submit CAPAs via email or fax, following up with originals

CAPA Review The audit program director (APD) reviews the corrective and preventative action plan to determine if the response is Acceptable. If the CAPA is not Acceptable, clarification of additional information will be requested. The CAPA will be submitted to the CTMB If the CTMB requires additional information, they will contact the Alliance

Writing a Satisfactory CAPA Address each issue listed in audit report as needing follow-up. Address 3 questions: l l l Why did this deficiency occur? (i.e, what was the problem?) Has the specific problem been corrected? (i.e. has the outstanding data in question been submitted? Has the patient been re-consented with the updated consent form?) What plan has been implemented to ensure this type of deficiency will not occur in the future?

Samples of Acceptable/ Unacceptable Corrective Action Plans

IRB Deficiency Major Deficiency Update #6 posted on 02/15/14 has not been submitted to the IRB. Partially Acceptable CAPA As updates are identified, they will be entered on the Outlook calendar to submit and track.

IRB Consent Content Deficiency Major Deficiency The local ICF does not include sample submission question #1 from page 2 of the model consent. This study is still open to new enrollment. Partially Acceptable CAPA A revision has been submitted to the IRB that includes all model consent questions. The site will now use the consent content checklist and review local consents compared to model consents.

Pharmacy Deficiency Major Deficiency The new ORAL DARF is not in use as per the PMB required date of September 1, 2014 for two studies. Acceptable or Unacceptable Plan? Two new sections have been added to our Pharmacy policy (see attached). One is mandating use of Oral DARF and the other is to include the CTMB Guidelines section 5.3. Pharmacy staff have been reeducated.

Treatment Deficiency Major Deficiency Dose modification error for Cycle 4. A 25% dose was warranted and the patient received a 40% dose reduction. This is greater than 10% margin of error. Acceptable or Unacceptable Plan? In reviewing these, I believe she did a very good job overall, but there were some confusing items which were misinterpreted. I believe that with her experience now, the next case would be much better.

Data Quality Deficiency Major Deficiency Per the Alliance Pathology Coordinating Office, the study required blood samples and blocks were not submitted. Acceptable or Unacceptable Plan? This was an isolated event and we do not feel it will occur again.

Data Quality Deficiency Major Deficiency Data forms for treatment, AE and disease response have not been submitted since cycle #7 (11/19/12). Patient had progressive disease on 11/26/2013. Acceptable or Unacceptable Plan? All forms have been submitted. The cancer center has hired an additional experienced CRA. Monthly staff meetings will cover data submission schedules. A quarterly review of data will be performed by the office manager.

Two Consecutive Unacceptable Ratings? (In the same component) CTMB section 6.3.2: Probation of Participating Institutions The institution will be placed on probation The Group may assign a mentor A site improvement plan must be developed to address key infrastructural issues contributing to poor performance (ALL of this in addition to the corrective and preventative action plan.)

Example: Site Improvement Plan for IRB The local IRB policies were revised in response to the audit findings The main member network will cover the costs of the site s CRP to attend the audit prep workshop at the next Alliance group meeting The Lead CRP will perform two IRB audits of the affiliate over the next year

Contact Information l Barbara Barrett l bbarrett@uchicago.edu l Phone: (312) 206-8216 l Fax: (312) 345-0117

Additional Contact Information l Josh Lachewitz, Audit Coordinator l jlachewitz@uchicago.edu l Phone: (773) 702-9973 l Fax: (312) 345-0117

Questions?

Thank you!

2014 Fall Group Meeting November 6 9 / Chicago, IL